Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC

References

• Beyene TJ, Hoek H, Zhang Y, et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013. Lancet 2015;385:117-71
   PubMed Web of Science ®Google Scholar
• Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005;172:523-9
   PubMed Web of Science ®Google Scholar
• Shlomi D, Ben-Avi R, Balmor GR, et al. Screening for lung cancer: time for large-scale screening by chest computed tomography. Eur Respir J 2014;44:217-38
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
   PubMed Web of Science ®Google Scholar
• Lung.org. Trends in COPD morbidity and mortality [Internet]. Washington, DC: American Lung Association; 2013. Available from: http://www.lung.org/assets/documents/research/copd-trend-report.pdf [cited August 5, 2015]
   Google Scholar
• Ford ES, Croft JB, Mannino DM, et al. COPD surveillance—United States, 1999–2011. Chest J 2013;144:284-305
   PubMed Web of Science ®Google Scholar
• Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest 2015;148:971-85
   PubMed Web of Science ®Google Scholar
• Mannino D, Aguayo S, Petty T, et al. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003;163:1475-80
   PubMed Web of Science ®Google Scholar
• Wasswa-Kintu S, Gan WQ, Man SF, et al.. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005;60(7):570-5
   Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
   PubMed Web of Science ®Google Scholar
• Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis 2016;10:72-84
   PubMed Web of Science ®Google Scholar
• Barnes D, Celli BR. Systemic manifestations and comorbidities of COPD. European Respiratory Journal 2009;33(5):1165-1185. The definitive review on the key features that define malignancy
   Web of Science ®Google Scholar
• Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer 2013;13:233-45
   PubMed Web of Science ®Google Scholar
• Belinsky SA, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-55
   PubMed Web of Science ®Google Scholar
• de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease—incidence and predicting factors. Am J Respir Crit Care Med 2011;184:913-19
   PubMed Web of Science ®Google Scholar
• Powell HA, Iyen-Omofoman B, Baldwin DR, et al. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. J Thorac Oncol 2013;8:6-11
   PubMed Web of Science ®Google Scholar
• Cancer.gov. Cancer Trends Progress Report—2011/2012 Update. Costs of Cancer Care [Internet]. Bethesda, MD: US National Institutes of Health. National Cancer Institute; [cited October 15, 2015]. Available from: https://progressreport.cancer.gov/sites/default/files/archive/report2011.pdf
   Google Scholar
• Nhlbi.nih.gov. Morbidity & mortality: 2007 chartbook on cardiovascular, lung, and blood diseases. [Internet]. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. Available from: http://www.nhlbi.nih.gov/resources/docs/07-chtbk.pdf [cited November 1, 2015]
   Google Scholar
• Nhlbi.nih.gov. Morbidity & mortality: 2009 chartbook on cardiovascular, lung, and blood diseases. [Internet]. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2009. Available from http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf [cited November 5, 2015]
   Google Scholar
• Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism costs of chronic obstructive pulmonary disease among adults aged ≥18 years in the United States for 2010 and projections through 2020. Chest 2015;147:31-45
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (mNSCLC). Lung Cancer 2008;61:405-15
   PubMed Web of Science ®Google Scholar
• Hoverman JR, Robertson SM. Lung cancer: a cost and outcome study based on physician practice patterns. Dis Manag 2004;7:112-23
   PubMedGoogle Scholar
• Lang K, Marciniak MD, Faries D, et al. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Value Health 2009;12:481-8
   PubMed Web of Science ®Google Scholar
• Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999–2000. J Clin Oncol 2004;22:3524-30
   PubMed Web of Science ®Google Scholar
• Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005;50:143-54
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008;14:297-306
   PubMed Web of Science ®Google Scholar
• Duh MS, Reynolds Weiner J, Lefebvre P, et al. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin 2008;24:967-74
   PubMed Web of Science ®Google Scholar
• Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009;15:669-82
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971-8
   PubMed Web of Science ®Google Scholar
• Seer.cancer.gov. Overview of the SEER Program [Internet]. Bethesda, MD: National Cancer Institute; 2014. Available from: https://seer.cancer.gov/about/overview.html [accessed February 2, 2015]
   Google Scholar
• Healthcaredelivery.cancer.gov. SEER-Medicare: Medicare Claims Files [Internet]. Bethesda, MD: National Cancer Institute; 2014. Available from: https://healthcaredelivery.cancer.gov/seermedicare/medicare/claims.html [accessed March 15, 2015]
   Google Scholar
• Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1991;31:732-48
   Web of Science ®Google Scholar
• Simoni-Wastila L, Keri Yang HW, Blanchette CM, et al. Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population. Curr Med Res Opin 2009;25:2729-35
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000;67:495-501
   Google Scholar
• Garcia-Aymerich J, Farrero E, Felez MA, et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003;58:100-5
   PubMed Web of Science ®Google Scholar
• Lau AC, Yam LY, Poon E. Hospital re-admission in patients with acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2001;95:876-84
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Monso E, Marrades RM, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med 2001;164:1002-7
   PubMed Web of Science ®Google Scholar
• Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005;26:414-19
   PubMed Web of Science ®Google Scholar
• Cao Z, Ong KC, Eng P, et al. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006;11:188-95
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MÁ, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31
   PubMed Web of Science ®Google Scholar
• Gadoury MA, Schwartzman K, Rouleau M, et al. Self-management reduces both short-and long-term hospitalisation in COPD. Eur Respir J 2005;26:853-7
   PubMed Web of Science ®Google Scholar
• Bahadori K, FitzGerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation–systematic review. Int J Chronic Obstr Pulm Dis 2007;2:241
   PubMedGoogle Scholar
• Mayer DK, Travers D, Wyss A, et al. Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol 2011;29:2683-8
   PubMed Web of Science ®Google Scholar
• Kotajima F, Kobayashi K, Sakaguchi H, et al. Lung cancer patients frequently visit the emergency room for cancer-related and-unrelated issues. Mol Clin Oncol 2014;2:322-6
   PubMedGoogle Scholar
• Sadik M, Ozlem K, Huseyin M, et al. Attributes of cancer patients admitted to the emergency department in one year. World J Emerg Med 2014;5:85-90
   PubMedGoogle Scholar
• Kumbhare SD, Beiko T, Wilcox SR, et al. Characteristics of COPD patients using United States emergency care or hospitalization. Chronic Obstr Pulm Dis 2016;3:539
   PubMed Web of Science ®Google Scholar
• Wouters EFM. Nutrition and metabolism in COPD. Chest 2000;117(5 Suppl 1):274S-280S
   PubMed Web of Science ®Google Scholar
• Hallin R, Gudmundsson G, Ulrik CS, et al. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med 2007;101:1954-60
   PubMed Web of Science ®Google Scholar
• Liu Y, Pleasants RA, Croft JB, et al. Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respir Med 109:851-9
   PubMed Web of Science ®Google Scholar
• Verbrugge LM, Patrick DL. Seven chronic conditions: their impact on US adults’ activity levels and use of medical services. Am J Public Health 1995;85:173-82
   PubMed Web of Science ®Google Scholar
• Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Ann Intern Med 2000;160:2653-8
   Google Scholar
• Cipriano LE, Romanus D, Earle CC, et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health 2011;14:41-52
   PubMed Web of Science ®Google Scholar
• Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:IV-3-IV-18
   Web of Science ®Google Scholar